CML MRD1 Viral Load Quantitative Test Cost in UAE
At DNA Labs UAE, we offer the CML MRD1 Viral Load Quantitative Test at a cost of AED 2040.0. This diagnostic test is used to measure the amount of viral load in a patient’s blood sample. It is specifically designed for Chronic Myeloid Leukemia (CML) patients who are being treated with targeted therapy drugs, such as tyrosine kinase inhibitors (TKIs).
Symptoms and Diagnosis
CML is a type of cancer that affects the bone marrow and causes the overproduction of white blood cells. Common symptoms of CML include fatigue, weight loss, night sweats, and enlarged spleen. Diagnosis of CML is usually done through a blood test, which may show abnormal levels of white blood cells and the presence of the BCR-ABL gene mutation.
Test Details
The CML MRD1 Viral Load Quantitative Test is used to monitor the response to TKI treatment and assess the level of minimal residual disease in the patient’s blood. Minimal residual disease refers to the small number of cancer cells that may remain in the body after treatment, even when the patient is in remission.
The test measures the amount of BCR-ABL gene transcripts, which are specific to CML, in the patient’s blood sample. The results are reported as a ratio or percentage of BCR-ABL gene transcripts to a reference gene. A lower ratio or percentage indicates a better response to treatment and a lower level of minimal residual disease.
Test Components and Price
The CML MRD1 Viral Load Quantitative Test is performed using Real Time PCR method. The test type is viral and it is conducted in the Genetics department. The cost of the test is AED 2040.0.
Report Delivery
The report for the CML MRD1 Viral Load Quantitative Test is delivered via email within 3rd working day. The email report is sent within 36 hours. Additionally, the report can also be obtained over the phone within 24 hours.
Pre Test Information
Prior to the test, patients are required to sign a consent document and bring any clinical history related to CML MRD1 Viral Load Quantitative Test.
Importance of the Test
The CML MRD1 Viral Load Quantitative Test plays a crucial role in the management of CML patients receiving targeted therapy. It allows healthcare providers to monitor the patient’s response to treatment and make necessary adjustments if needed. This personalized approach to treatment leads to improved patient outcomes.
Overall, the CML MRD1 Viral Load Quantitative Test is an essential tool in the diagnosis and management of CML. It helps in assessing the level of minimal residual disease and guides treatment decisions for CML patients.
| Test Name | CML MRD1 Viral Load Quantitative Test |
|---|---|
| Components | |
| Price | 2040.0 AED |
| Sample Condition | Whole Blood |
| Report Delivery | 3rd Working Day Email:-36 hours. On phone: 24 hours |
| Method | Real Time PCR |
| Test type | Viral |
| Doctor | Physician |
| Test Department: | Genetics |
| Pre Test Information | Need to sign Consent document and bring any clinical history of patient forCML MRD1 Viral Load QuantitativeTest |
| Test Details |
CML MRD1 (Minimal Residual Disease 1) Viral Load Quantitative Test is a diagnostic test used to measure the amount of viral load in a patient’s blood sample. This test is specifically designed for Chronic Myeloid Leukemia (CML) patients who are being treated with targeted therapy drugs, such as tyrosine kinase inhibitors (TKIs). CML is a type of cancer that affects the bone marrow and causes the overproduction of white blood cells. TKIs are commonly used to treat CML by inhibiting the activity of the BCR-ABL gene, which is responsible for the abnormal growth of white blood cells. The CML MRD1 Viral Load Quantitative Test is used to monitor the response to TKI treatment and assess the level of minimal residual disease in the patient’s blood. Minimal residual disease refers to the small number of cancer cells that may remain in the body after treatment, even when the patient is in remission. The test measures the amount of BCR-ABL gene transcripts, which are specific to CML, in the patient’s blood sample. The results are reported as a ratio or percentage of BCR-ABL gene transcripts to a reference gene. A lower ratio or percentage indicates a better response to treatment and a lower level of minimal residual disease. The CML MRD1 Viral Load Quantitative Test is typically performed at regular intervals during and after treatment to monitor the patient’s response and guide treatment decisions. It helps healthcare providers determine if the current treatment is effective or if adjustments need to be made. Overall, this test plays a crucial role in the management of CML patients receiving targeted therapy, allowing for personalized treatment plans and improved patient outcomes. |
